These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24033757)

  • 1. What do we learn from repeated population analyses?
    Duffull SB; Wright DF
    Br J Clin Pharmacol; 2015 Jan; 79(1):40-7. PubMed ID: 24033757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enoxaparin Population Pharmacokinetics in the First Year of Life.
    Moffett BS; Galati M; Mahoney D; Lee-Kim Y; Teruya J; Shah MD; Yee DL
    Ther Drug Monit; 2017 Dec; 39(6):632-639. PubMed ID: 28937536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leveraging physiological data from literature into a pharmacokinetic model to support informative clinical study design in pregnant women.
    van Hasselt JG; Green B; Morrish GA
    Pharm Res; 2012 Jun; 29(6):1609-17. PubMed ID: 22246291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of enoxaparin in early stage of paediatric liver transplantation.
    Oualha M; Chardot C; Debray D; Lesage F; Harroche A; Renolleau S; Treluyer JM; Urien S
    Br J Clin Pharmacol; 2018 Jun; 84(6):1206-1214. PubMed ID: 29423936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a Pharmacy-Managed Pharmacokinetic Dosing Program.
    Meyenburg LK; Crannage AJ; Murphy JA; Korobey MJ
    J Pharm Pract; 2015 Dec; 28(6):529-34. PubMed ID: 25107423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Pharmacokinetics of Enoxaparin in Pediatric Patients.
    Moffett BS; Lee-Kim Y; Galati M; Mahoney D; Shah MD; Teruya J; Yee D
    Ann Pharmacother; 2018 Feb; 52(2):140-146. PubMed ID: 28962537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Anti-Factor Xa Levels of Patients Undergoing Colorectal Surgery Given Once-Daily Enoxaparin Prophylaxis: A Clinical Study Examining Enoxaparin Pharmacokinetics.
    Pannucci CJ; Fleming KI; Bertolaccini CB; Prazak AM; Huang LC; Pickron TB
    JAMA Surg; 2019 Aug; 154(8):697-704. PubMed ID: 31116389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction.
    Bruno R; Baille P; Retout S; Vivier N; Veyrat-Follet C; Sanderink GJ; Becker R; Antman EM
    Br J Clin Pharmacol; 2003 Oct; 56(4):407-14. PubMed ID: 12968985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased Enoxaparin Dosing Requirements for Treatment of Deep Vein Thrombosis in a Severely Burned Patient: Case Report and Literature Review.
    Yost RJ; Haan BJ; Mangan KC
    Pharmacotherapy; 2018 Nov; 38(11):e82-e86. PubMed ID: 30129107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome.
    Hulot JS; Montalescot G; Lechat P; Collet JP; Ankri A; Urien S
    Clin Pharmacol Ther; 2005 Jun; 77(6):542-52. PubMed ID: 15961985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased enoxaparin dosing is required for obese children.
    Lewis TV; Johnson PN; Nebbia AM; Dunlap M
    Pediatrics; 2011 Mar; 127(3):e787-90. PubMed ID: 21321026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
    Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M
    Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective evaluation of a D-optimal designed population pharmacokinetic study.
    Green B; Duffull SB
    J Pharmacokinet Pharmacodyn; 2003 Apr; 30(2):145-61. PubMed ID: 12942685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin.
    Limsakun T; Dishy V; Mendell J; Pizzagalli F; Pav J; Kochan J; Vandell AG; Rambaran C; Kobayashi F; Orihashi Y; Warren V; McPhillips P; Zhou J
    J Clin Pharmacol; 2020 Jun; 60(6):691-701. PubMed ID: 32106339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enoxaparin and antifactor Xa levels in acute burn patients.
    Lin H; Faraklas I; Cochran A; Saffle J
    J Burn Care Res; 2011; 32(1):1-5. PubMed ID: 21124231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individualized compared with conventional dosing of enoxaparin.
    Barras MA; Duffull SB; Atherton JJ; Green B
    Clin Pharmacol Ther; 2008 Jun; 83(6):882-8. PubMed ID: 17928819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rethinking the one-size-fits-most approach to venous thromboembolism prophylaxis after radical cystectomy.
    Corona LE; Singhal U; Hafez K; Herrel LA; Kaffenberger SD; Montgomery JS; Morgan TM; Weizer AZ; Qin Y; Ambani SN
    Urol Oncol; 2020 Oct; 38(10):797.e1-797.e6. PubMed ID: 32624425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment.
    Sanderink GJ; Guimart CG; Ozoux ML; Jariwala NU; Shukla UA; Boutouyrie BX
    Thromb Res; 2002 Feb; 105(3):225-31. PubMed ID: 11927128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of population pharmacokinetic data using NONMEM and WinBUGS.
    Duffull SB; Kirkpatrick CM; Green B; Holford NH
    J Biopharm Stat; 2005; 15(1):53-73. PubMed ID: 15702605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of subcutaneous low molecular weight heparin (enoxaparin) in dogs.
    Lunsford KV; Mackin AJ; Langston VC; Brooks M
    J Am Anim Hosp Assoc; 2009; 45(6):261-7. PubMed ID: 19887383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.